San Francisco, California, September 19, 2017: TMR Research observes that global fungal infections market is likely to witness a steady growth rate in the coming years. The research report, titled “Fungal Infections Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” offers an in-depth understanding of the drivers and restraints defining the trajectory of the overall market. It evaluates the various products available in the global market along with mentioning the impact the new products would bring. The publication also discusses the perils of fungal infections if left untreated, a factor that has been identified as a key market driver. The research report has been compiled using primary and secondary research methodologies that allow the readers a clear understanding of the overall market.
The global fungal infections market is being driven by both high incidence and growing awareness of it. The global market is poised to experience a phenomenal rise in the coming few years as the rate of systemic infections are expected to remain on the rise. Compromised immune systems, increasing unhygienic conditions in poverty-stricken areas, and growing number of diabetics around the world are the primary growth drivers for the global fungal infections market. As the world witnesses a significant rise in the geriatric population, it is also likely to see a high rate of fungal infections.
Currently, the global fungal infections market offers systemic and topical treatments. The report predicts that continuous introduction of new products and persistent research and development activities are expected to augment the growth of the global fungal infections market. Additionally, the fast-tracked drug approvals by the Food and Drug Administration (FDA) are also projected fuel the soaring revenue of the global market. These treatments are used for treating fungal infections of the lungs, skin, digestive tract, skin, liver, genitals, and several other tissues. Presently, companies are making a significant investment in finding solutions to treat fungal keratitis, hisptoplasmosis, and mucormycosis, which are rare fungal infections.
Geographically, the global fungal infections market is segmented into the Middle East and Africa, Europe, North America, Asia Pacific, and Latin America. Of these, North America holds a leading share in the global market due better healthcare facilities and supportive reimbursement policies. Additionally, the remarkable infrastructural facilities in the region are also expected to boost its growth in the near future. The report also predicts that Asia Pacific fungal infections market is anticipated to see a significant growth due to a vast population base and increasing expenditure on healthcare services. The research report also anticipates that the growing investments by key players in developing countries to set up manufacturing units for medical solutions are likely to benefit the regional market in the coming years. The emerging economies of Africa and Latin America are also projected propel the growth of the global market in the near future.
Some of the leading players operating in the global fungal infections market are Eisai Co. Ltd., Eli Lily and Company, Samyang Corporation, Helix Biomedic Inc., and AstraZeneca PLC. The research report dedicates an entire chapter to explain the competitive landscape present in the global market along with an evaluation of the threat from new entrants. The publication also includes a detailed assessment of the research and development activities of these players, their business and marketing strategies, and their financial outlooks. Furthermore, the document also provides valuable insights into the various dynamics by assessing the micro and macro elements of the market. The research report is complete with comments and recommendations by market experts in order to provide the readers a holistic view of the global fungal infections market.
Click on the link below to request a sample copy of the report